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EXPRESSION OF HUMAN BETA-DEFENSINS-1‒4 IN THYROID 
CANCER CELLS AND NEW INSIGHT ON BIOLOGIC ACTIVITY 
OF hBD-2 IN VITRO
O.V. Zhuravel, O.L. Gerashchenko, M.R. Khetsuriani, M.A. Soldatkina, P.V. Pogrebnoy*
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
of NAS of Ukraine, Kyiv 03022, Ukraine
The study was aimed on analysis of human beta-defensin-1–4 (hBDs) mRNA expression in cultured thyroid cancer cells and evaluation 
of effects of recombinant hBD-2 (rec-hBD-2) on growth patterns, migration properties and expression of E-cadherin and vimentin in these 
cells. Methods: The study was performed on cultured follicular thyroid cancer WRO cells, papillary thyroid cancer TPC1 cells, and ana-
plastic thyroid cancer KTC-2 cells. For analysis of hBD-1–4 mRNA expression in thyroid cancer cells, semiquantitative RT-PCR was 
used. Effects of rec-hBD-2 on cell proliferation, viability, and migration were analyzed using direct cell counting, MTT test, and scratch 
assay respectively. Expression of vimentin and E-cadherin was evaluated by quantitative PCR (qPCR). Results: By the data of RT-PCR, 
all three studied thyroid cancer cell lines express hBD-1 and -4 mRNA, but not hBD-2 mRNA, while hBD-3 expression was detected 
in WRO and KTC-2 cells. The treatment of TPC-1, WRO, and KTC-2 cells with 100–1000 nM rec-hBD-2 resulted in significant 
concentration-dependent suppression of cell proliferation, viability, and migratory property. By the data of qPCR, significant up-regu-
lation of vimentin expression was registered in KTC-2 and WRO cells treated with 500 nM rec-hBD-2. Significant down-regulation 
of E-cadherin expression (p < 0.05) was detected only in KTC-2 cells treated with the defensin. Also, it has been shown that TPC-1 cells 
treated with 500 nM rec-hBD-2 acquired more elongated morphology. Conclusion: The data demonstrate that hBD-2 in concentrations 
higher than 100 nM exerts significant concentration-dependent suppression of thyroid cancer cell growth and migration, and affects vi-
mentin and E-cadherin expression dependent on histologic type of thyroid cancer cells.
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The incidence of thyroid cancer in Ukraine is con-
stantly rising and in 2012 it comprises 1.8% of all 
cancers [1]. Thyroid carcinoma is represented by five 
major histological types — papillary carcinoma (more 
than 80% cases), follicular, medullary, poorly dif-
ferentiated, and anaplastic carcinoma. These types 
of thyroid cancer have different prognosis, the course 
of the disease and require different treatment. 
At the same time, fundamental aspects of thyroid 
tumorige nesis share a number of common underlying 
molecular mechanisms, among which the process 
of epithelial-mesenchymal transition (EMT) has been 
recognized recently among important events which 
determine metastatic progression [2, 3]. Thyroid 
cancer cells are often used as model for investigation 
of EMT mechanisms and elements of EMT machinery.
EMT and reverse event — mesenchymal-epithelial 
transition (MET) represent recently discovered funda-
mental processes of epithelial cell plasticity control. 
During EMT epithelial cells acquire the special proper-
ties of mesenchymal cells: cell morphology is changed 
to a spindle shaped mesenchymal type, migratory 
and invasive properties of the cells are enhanced, and 
expression of some markers (in particular, vimentin 
and E-cadherin) is altered. During EMT, expression 
of E-cadherin, a cell-to-cell adhesion molecule, 
is down-regulated, while expression of structural 
protein vimentin is up-regulated.
It is accepted that EMT could occur in three diffe-
rent biologic settings — embryogenesis/organoge-
nesis (type 1 EMT), tissue regeneration /wound repair 
(type 2 EMT), and cancer progression/metastasis 
(type 3 EMT) [4, 5]. It is supposed that all mentioned 
types of EMT represent different biologic processes 
but may have a lot in common in regard to underly-
ing molecular events and elements. EMT machinery 
is under close investigation at present time due to its 
crucial role in tumor metastasis.
In the present study we have investigated a possible 
effect of human beta-defensin-2 (hBD-2) on expres-
sion of special EMT markers in thyroid cancer cells. 
hBD-2 is an inducible cationic peptide, a member 
of hBD family of antimicrobial peptides, involved in an-
timicrobial protection of human body and in wound he-
aling processes [6–9]. In a number of studies it has been 
demonstrated that some hBDs, especially hBD-2, play 
an important role in wound repair affecting keratinocyte 
migration and proliferation and accelerating wound he-
aling. Hypothetically, these antimicrobials could be in-
volved in II type EMT, however, this hypothesis has not 
been analyzed yet. From the other hand, in in vitro set-
ting it has been shown that hBD-2 and hBD-4 may regu-
late the growth of cultured human cancer cells via cell 
cycle control and affect their migratory properties and 
malignant potential in a concentration-dependent man-
ner [10–12]. Also, deregulation of expression of some 
defensins in human tumors of different histogenesis 
has been shown, and possible implication of these 
antimicrobials in tumor development has been stated 
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[13, 14]. Moreover, the latest studies demonstrated 
an association between expression of hBD-1 and in oral 
squamous cell carcinoma and migratory and invasive 
properties of OSCC cells, and suggested that hBD-1 ex-
pression in OSCC may be considered as prognostic 
marker in this type of cancer [15]. However, in regard 
to thyroid cancer, no data on expression and biological 
effects of hBDs have been reported so far.
Therefore, in the present study we have analyzed 
the profile of hBD-1–4 mRNA expression in three hu-
man thyroid cancer cell lines originating from papillary 
carcinoma (TPC-1 cell line), follicular carcinoma (WRO 
cell line), and anaplastic cancer (KTC-2 cell line). Also, 
we have studied an influence of recombinant hBD-2 (rec-
hBD-2) on proliferation and viability of these cells, their 
morphology and migratory properties, and expression 
of important EMT markers — E-cadherin and vimentin. 
Taken together, our data demonstrate that hBD-2 not 
only controls the growth and migratory pro perties of hu-
man thyroid cancer cells but also significantly affects 
expression levels of EMT markers and alters cell mor-
phology toward spindle-shaped phenotype.
MATERIALS AND METHODS
Cell lines. In the study, follicular thyroid cancer 
WRO cell line, papillary thyroid cancer TPC1 cell line, 
and anaplastic thyroid cancer KTC-2 cell line were 
used. The cells were cultured in DMEM culture medium 
supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin G sodium, 100 μg/mL strepto-
mycin sulfate in humidified 5% CO2 atmosphere at 37 °C.
Preparation of rec-hBD-2. To study the effect 
of exogenous defensin on cell growth, we used puri-
fied rec-hBD-2 [16]. In brief, E.coli BL21(DE3) cells 
transformed with GST-hBD-2-recombinant plasmid 
were induced with 1 mM IPTG for 6 h, pelleted by cen-
trifugation, resuspended in lysis buffer (50 mМ Tris-HCl, 
pH 7.6; 250 mМ NaCl; 1% Triton Х-100 and cocktail 
of protease and phosphatase inhibitors), and disrupted 
using ultrasound disintegrator (UD-11 Automatic, Po-
land). Then cell lysate was applied to affinity chromatog-
raphy on glutathione-agarose co lumn (GE Healthcare, 
Sweden) with following cleavage of the defensin from 
fusion protein by thrombin digestion. hBD-2 peptide 
was further purified by reverse phase chromatography 
on Sep-Pack C18 cartridge (Waters, USA), vacuum-
dried, and re-dissolved in water. Protein concentration 
was determined by UV absorbance at 280 nm using 
spectrophotometer Nanodrop-1000 (USA).
Direct cell counting. To study the effect of rec-
hBD-2 on cell proliferation, KTC-2, TPC-1, and WRO 
cells were routinely cultured in 24-well plates (5•104 cells 
per well) to nearly 50% confluence, then culture medium 
was replaced with fresh DMEM supplemented with 2.5% 
FBS. Rec-hBD-2 was added into the medium in con-
centrations of 0.1; 1; 10; 100; 500; 1000 nM, followed 
by culturing for 48 h. After the treatment, cells were 
washed with PBS, detached with trypsin, and counted 
in hemocytometer. The percentage of dead cells was 
analyzed using trypan blue staining.
MTT assay. To evaluate the effect of rec-hBD-2 on cell 
viability, MTT-test has been applied [17]. Thyroid cancer 
cells were seeded into 96-well plates (7•103 cells per 
well) and incubated with rec-hBD-2 at the concentration 
range from 100 pM to 1 μM in DMEM supplemented with 
2.5% FBS for 48 h. Then cells were routinely treated with 
МТТ (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetra-
zolium bromide) according to standard protocol, and 
colorimetric reaction was evaluated with the use of ELISA 
reader (Awareness Technology Inc, USA) at  = 545.
Scratch wound healing assay. An effect of rec-
hBD-2 on mobility of cultured human thyroid can-
cer cells was performed by scratch wound healing 
assay [18]. The cells were seeded in 6-well plates 
(1.5•105 cells per well) and routinely grown till 80% 
confluence, than a scratch was performed using a tip, 
and the cells were grown for next 24 h in the presence 
of 500 or 1000 nM rec-hBD-2 in serum free medium. 
Then the cell migration into wound area was examined 
using inverted microscope Axioplan (Zeiss, Germany).
RT-PCR analysis of hBD-1–4 mRNA expres-
sion in thyroid cancer cells. To evaluate the hBD-
1–4 mRNA expression in thyroid cancer cells, total RNA 
was extracted from KTC-2, WRO and TPC-1 cell lysates 
using Trizol RNA Isolation Kit (Neogene, Russian Fed-
eration) according to manufacturer’s protocol. For 
detection of hBD-1–4 mRNA expression, semiquan-
titative RT-PCR analysis was performed using specific 
primers (Table). The expression level of beta-actin (the 
house-keeping gene) served as a loading control. The 
products of RT-PCR were routinely analyzed by elec-
trophoresis in agarose gel.
Table. Primers for the genes of interest
Gene Primers
DEFB1 (hBD-1) F: TGTTGCCTGCCAGTCGCCATGAG
R: TCACTTGCAGCACTTGGCCTTCCC
DEFB4 (hBD-2) F: 5´-GAAGCTCCCAGCCATCAGCC
R: 5´-GTCGCACGTCTCTGATGAGGGA
DEFB103 (hBD-3) F: CCTGTTTTTGGTGCCTGTTCC
R: CTTTCTTCGGCAGCATTTTCG
DEFB104 (hBD-4) F: GAAGCTCCCAGCCATCAGCC
R: GTCGCACGTCTCTGATGAGGGA
Beta-actin F: CTGGAACGGTGAAGGTGACA
R: AAGGGACTTCTTGTAACAATGCA
Quantitative PCR analysis of vimentin and 
 E-cadherin expression in thyroid cancer cells. Ex-
pression of vimentin and E-cadherin in KTC-2, WRO and 
TPC-1 cells treated with 500 nM rec-hBD-2 for 24 h, was 
analyzed  using qPCR. Total RNA was extracted from cell 
lysates using Trizol RNA Isolation Kit (Neogene, Rus-
sian Federation) according to manufacturer’s protocol. 
2 g of RNA were reverse transcribed using an M-MLV 
Reverse Transcriptase, Ribonuclease Inhibitor Ribolock 
(Thermo Scientific Inc., USA) and oligo(dT)18 primer. 
Expression levels of vimentin and E-cadherin genes 
were analyzed by qPCR on ABI 7500 Fast real-time PCR 
system (Applied Biosystems, USA) using 0.2 μM of each 
primer and SYBR Green master mix (Thermo Scientific 
Inc., USA) and 1 l cDNA. The following conditions 
of reaction were used: 10 min 95 °C initial denaturation; 
40 cycles15 s 95 °C denatu ration, 60 s 60 °C primer 
annealing/elongation. The fluorescence was recorded 
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during the annealing/elongation step in each cycle. 
A  melting curve analysis was performed at the end 
of each PCR by gradually increasing the temperature 
from 60 to 95 °C while recording the fluorescence. A sin-
gle peak at the melting temperature of the PCR-product 
confirmed primer specificity. The β2-microglobulin 
was used as a reference gene to standar dize the level 
of other transcripts. Following primers were used for 
vimentin: F —  5´-GTGAATACCAAGACCTGCTCAA-3´, 
R — 5`-AGGGAGGAAAAGTTTGGAAGAG-3´; for 
 E-cadherin: F —  5´-  CTGGTTCAGATCAAATCCAACA-3´, 
R — 5´-CTTCAGCCATCCTGTTTCTCTT-3´ and 
 β2-microglobulin: F — 5´-CCGTGTGAACCATGT-
GACTTTGTC-3´, R — 5´-TGCGGCATCTTCAAACCTC-
CATGATG-3´. The relative amounts of the transcripts 
were first normalized to the reference gene and then 
normalized to the gene expression level in the untreated 
samples according to the 2−ΔΔCt method [19], statistical 
analysis was performed using statistical application 
of Microsoft Excel software based on t-test with p < 
0.05 repre senting significance.
Statistical analysis. Data on direct cell counting and 
MTT data were reported as the mean ± SD of values ob-
tained from three independent experiments and analyzed 
by Student’s t-test to assess the statistical significance 
of the differences between the groups. A statistically 
significant difference was considered at p < 0.05.
RESULTS AND DISCUSSION
Expression of hBD-1–4 mRNA in human thy-
roid cancer cells. Semiquantitative RT-PCR analysis 
of expression of hBD-1–4 mRNA in human papillary 
carcinoma TPC-1 cells, follicular carcinoma WRO cells, 
and anaplastic carcinoma KTC-2 cells has revealed 
the presence of mRNA for hBD-1 and -4 and no detec-
table hBD-2 expression in all cell lines. hBD-3 expres-
sion was registered in 2 from 3 cell lines (WRO and 
KTC-2 cells). WRO cells were characterized by high 
expression of hBD-3 while TPC1 — by high expression 
of hBD-4 (Fig. 1). So, thyroid cancer cells of different 
histological type express beta-defensins-1,-3 and -4, 
but not hBD-2. To our knowledge, it is the first report 
on hBDs expression in thyroid cancer cells. Up-to-
date, just a single study reported on low-level expres-
sion of hBD-4 mRNA in normal thyroid gland [20].
Effect of rec-hBD-2 on proliferation and viabi lity 
of human thyroid cancer cells in vitro. We have analyzed 
an effect of rec-hBD-2 on proliferation and viability of TPC-1, 
WRO, and KTC-2 cells. As it has been shown using direct 
cell counting technique (Fig. 2), in concentrations higher 
than 100 nM rec-hBD-2  exerted concentration-dependent 
growth suppression of the thyroid cancer cells, especially 
KTC-2 cells, and in concentrations lower than 100 nM exerts 
no significant influence on cell counts (see Fig. 2).
As it has been shown by MTT assay, viability 
of cultured TPC-1, WRO, and KTC-2 cells is affected 
by rec-hBD-2 in a similar concentration-dependent 
manner (Fig. 3). Our data have shown that in con-
centrations lower than 100 nM rec-hBD-2 had no sig-
nificant effect on viability of TPC-1 and WRO cells and 
stimulated viabi lity of KTC-2 cells at 100 pM concen-
tration (see Fig. 3). In all three cell lines significant 
suppression of cell viability in the presence of rec-
hBD-2 in concentrations higher than 100 nM has been 
registered. No viable cells have been revealed after 
treatment of the cells with 1 μM rec-hBD-2.
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Fig. 1. RT-PCR analysis of hBDs mRNA expression in thyroid 
cancer cells: 1 — WRO; 2 — KTC-2; 3 — TPC1. β-actin is used 
as a house-keeping gene
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Fig.  2.  A concentrat ion-dependent  ef fect  of  rec-
hBD-2 on the number of viable cultured cells of TPC-1, KTC-2, 
and WRO lines. The number of attached cells was evaluated by di-
rect cell co unting. The data of three independent experiments 
are presented as the mean ± SD. *The difference is significant 
as compared to appropriate control (p < 0.05)
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Fig. 3. A concentration-dependent effect of rec-hBD-2 on vi-
ability of TPC-1, WRO, and KTC-2 cells (MTT analysis). The data 
of three independent experiments are presented as the mean 
± SD.*p < 0.05
The data on the influence of rec-hBD-2 on prolif-
eration and viability of thyroid cancer cells are in ac-
cordance with the reported earlier results on a concen-
tration-dependent growth suppressive effects of this 
defensin toward cancer cells of other histological 
types (such as carcinoma cells of A431 and A549 lines, 
cultured human melanoma cells [10, 12]). As it was 
reported, growth suppression caused by hBD-2 in vi-
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tro is exerted via cell cycle arrest at G1/S checkpoint, 
down-regulation of  cyclin D1 expression and activa-
tion of pRB [10, 12]. In the present research we did 
not study cell cycle distribution of thyroid cancer cells 
treated with rec-hBD-2; we suppose that the mecha-
nism of hBD-2 dependent growth suppression in thy-
roid cancer cells may be similarly exerted via blockage 
of cell cycle. Here, we have focused our attention 
on other effects of rec-hBD-2 in growth-inhibitory 
concentrations toward cultured thyroid cancer cells, 
in particular, its effects on morphology and migration 
ability of these cells, and on expression of common 
EMT markers — vimentin and E-cadherin.
Effect of rec-hBD-2 on thyroid cancer cell 
migration and morphology. To analyze a possible 
effect of rec-hBD-2 on cancer cell migration, wound 
healing assay has been applied. It was revealed that 
100 nM and 500 nM of rec-hBD-2 significantly sup-
pressed migration of TPC-1 cells (Fig. 4) as well as WRO 
and KTC-2 (data not shown). Also, we have noted 
an altered morphology of TPC-1 cells after 48 h treat-
ment with 500 nM or 1000 nM rec-hBD-2 (Fig. 5). 
TPC-1 cells treated with rec-hBD-2 acquire more elon-
gated fibroblast-like shape compared to the untreated 
control cells. No notable morphological changes in WRO 
and KTC-2 cells treated with 500 nM or 1000 nM rec-
hBD-2 were observed (data not shown).
From the reports of other authors it is known that 
some human defensins may affect cancer cell migra-
tion, in particular, hBD-1 suppresses migration and 
invasion of oral squamous cell carcinoma cells [15], 
hBD-3 suppresses head and neck cancer cell migra-
tion [21], hBD-4 may stimulate or inhibit migration 
of A431 and TPC-1 cells in scratch assay dependent 
on its concentration [11]. However, little is known yet 
about possible impact of defensins as peptides affect-
ing cell migratory capability in vivo as well as the mech-
anisms of defensin-dependent suppression of cell mi-
gratory properties. In our study, we detected not only 
hBD-2 dependent suppression of thyroid cancer cell 
migration, but also alterations in TPC-1 cell morphol-
ogy toward more elongated mesenchymal phenotype. 
Therefore, in the last part of our study we have studied 
the effects of rec-hBD-2 on expression levels of EMT 
markers in thyroid cancer cells in vitro.
Expression of vimentin and E-cadherin in thyroid 
cancer cells treated with rec-hBD-2. The study of ex-
pression of two common EMT markers — vimentin and 
E-cadherin — has been carried out using qPCR analysis 
in TPC-1, KTC-2 and WRO cells treated with 500 nM rec-
hBD-2 for 24 h. It has been found out that in KTC-2 cells 
treated with the defensin, expression level of vimentin 
was significantly higher, and E-cadherin — notably 
lower than in untreated control cells by 3.39 ± 0.19 and 
0.59 ± 0.034 times, respectively (p < 0.05) (Fig. 6). 
In WRO cells, treatment with defensin led to significant 
up-regulation of vimentin expression by 3.07 ± 0.13 times, 
and had a tendency for down-regulation of E-cadherin 
expression level (Fig. 6). In TPC-1 cells vimentin level was 
unaffected by rec-hBD-2 treatment while E-cadherin 
expression is undetectable in this cell line (Fig. 6).
To our knowledge, here we present the first evi-
dence on effects of hBD-2 on vimentin and E-cadherin 
expression in human cancer cells. Up-to-date, a recent 
study has reported on effects of synthetic human 
alpha-defensin-5 (HD-5), antimicrobial peptide pro-
duced by the Paneth cells on expression of E-cadherin 
in squamous cell line Het-1A in vitro [22]. Using immu-
nocytochemistry, flow cytometry, and  Western blotting, 
the authors showed that the E-cadherin expression was 
down-regulated in HD-5 treated cells and suppose that 
HD-5 produced by metaplastic Paneth cells may be in-
volved in the development of Barrett’s esophagus due 
to its ability to decrease E-cadherin expression [22].
In conclusion, the data of present research de-
monstrate that hBD-2 in concentrations higher than 
a b c
Fig. 4. Wound healing assay performed in TPC-1 cells treated with 100 nM (b) or 500 nM (c) rec-hBD-2 for 48 h. a — control un-
treated cells. The results of a typical experiment are presented. Magnification ×400
a b c
Fig. 5. Morphology of TPC1 cells treated with 500 nM rec-hBD2 (b) or 1000 nM rec-hBD2 (c) for 48 h. a — control cells. Magnification ×400
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100 nM exerts an inhibitory effect on cell growth and 
migration of three thyroid cancer cell lines. At the same 
time effects of hBD-2 on expression of vimentin and 
 E-cadherin strongly depended on thyroid cancer cell 
type. The most prominent up-regulation of vimentin 
expression and down-regulation of E-cadherin expres-
sion were observed in anaplastic thyroid cancer cells, 
and at lesser extent in follicular thyroid cancer cells 
while in papillary thyroid cancer cells vimentin expres-
sion seems to be unaffected by hBD-2 treatment, and 
acquired elongated morphology. Taken together, these 
data point on effects of hBD-2 toward some important 
EMT markers and gain new insight on the biological 
activity of this defensin toward cancer cells.
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Fig. 6. Relative expression of vimentin and E-cadherin mRNA in KTC-2, WRO, TPC-1 cells treated with 500 nM rec-hBD-2 for 24 h (2) 
(qPCR data) compared to untreated cells (1). The β2-microglobulin was used as a reference gene to standardize the level of other 
transcripts. The relative amounts of the transcripts were first normalized to the reference gene and then normalized to the gene 
expression level in the un-treated samples according to the 2−ΔΔCt method
